UPDATED: JAN 2, 2018 Broadens immunomodulatory peptide portfolio while also expanding route of administration capabilities PHILADELPHIA, January 2, 2018 (Newswire.com) - Longevity Biotech Inc. (LBT) has been awarded a Phase…
Read More
January 2, 2018 – Philadelphia, PA Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma.
Read More
October 30, 2017 – New York, NY Longevity Biotech will be attending the annual Michael J. Fox Foundation Parkinson’s Disease meeting in NYC.
Read More
October 27, 2017 – Philadelphia, PA Longevity Biotech is pleased to announce funding support from the National Multiple Sclerosis Society to our evaluate lead candidate, LBT-3627, as a potential treatment for MS.
Read More
Updated October 27, 2017 Launches preclinical development effort of LBT-3627 as a neuroprotective/repair treatment for Multiple Sclerosis. Philadelphia, PA, October 27, 2017 (Newswire.com) -Longevity Biotech, Inc. (LBT) has received an award from…
Read More
October 19, 2017 – San Francisco, CA Longevity Biotech will attend the Breakout Labs Annual Unboxing Event.
Read More
October 11, 2017 – Philadelphia, PA Longevity Biotech announces that the US Patent and Trademark Office has granted a key patent covering aspects of the Hybridtide® peptide technology platform.
Read More
UPDATED: OCT 11, 2017 PHILADELPHIA, October 11, 2017 (Newswire.com) - Longevity Biotech, Inc. (LBT) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.…
Read More
April 6, 2017 – New York, NY Longevity Biotech will attend the Breakout Labs East Coast Event
Read More
Our ever-increasing understanding of biological systems is providing a range of exciting novel biological targets, whose modulation may enable novel therapeutic options for many diseases. These targets include protein–protein and…
Read More